{"transactions":[{"id":905476,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-13T21:25:07.000Z","date":"2026-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":6155,"price":14.25,"value":87708.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards."}],"balance_after":871871,"source":{"system":"sec-edgar","filing":"0002064832-26-000006","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000006/form4.xml","form_type":"4"}},{"id":905475,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-13T21:25:07.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":15200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of Enanta common stock issued under a relative total stockholder return unit (\"rTSRU\") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026."}],"balance_after":878026,"source":{"system":"sec-edgar","filing":"0002064832-26-000006","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000006/form4.xml","form_type":"4"}},{"id":905474,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-13T21:25:07.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":4800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Enanta common stock issued under performance share units (\"PSUs\") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026."}],"balance_after":862826,"source":{"system":"sec-edgar","filing":"0002064832-26-000006","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000006/form4.xml","form_type":"4"}},{"id":979318,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-05T23:41:50.000Z","date":"2025-12-05","kind":"sale","planned":false,"acquired":false,"shares":4743,"price":14.23,"value":67492.89,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.46, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":858026,"source":{"system":"sec-edgar","filing":"0002064832-25-000057","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000057/form4.xml","form_type":"4"}},{"id":982048,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-03T21:34:07.000Z","date":"2025-12-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":1885,"price":14.12,"value":26616.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021."}],"balance_after":862769,"source":{"system":"sec-edgar","filing":"0002064832-25-000042","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000042/form4.xml","form_type":"4"}},{"id":987431,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-26T22:01:14.000Z","date":"2025-11-25","kind":"grant","planned":false,"acquired":true,"shares":310000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025)."}],"balance_after":310000,"derivative":{"exercise_price":13.66,"expiration_date":"2035-11-25","underlying":"Common Stock","underlying_shares":310000},"source":{"system":"sec-edgar","filing":"0002064832-25-000024","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000024/form4.xml","form_type":"4"}},{"id":1267823,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-14T21:35:58.000Z","date":"2025-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":7484,"price":5.59,"value":41835.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares of common stock automatically forfeited by the reporting person pursuant to the terms of the awards to cover withholding taxes due as a result of the settlement of the PSU awards."}],"balance_after":864654,"source":{"system":"sec-edgar","filing":"0001062993-25-002549","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299325002549/form4.xml","form_type":"4"}},{"id":1267822,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-14T21:35:58.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":25500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Enanta common stock issued under performance share units (\"PSUs\") that vested as a result of performance against two-year research and development milestones in the calendar 2023-2024 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2025."}],"balance_after":872138,"source":{"system":"sec-edgar","filing":"0001062993-25-002549","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299325002549/form4.xml","form_type":"4"}},{"id":1272051,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-13T01:09:35.000Z","date":"2025-02-12","kind":"purchase","planned":false,"acquired":true,"shares":45000,"price":5.69,"value":256050.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person's purchase of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 5,142 shares, all of which related to a \"sell to cover\" transaction required to satisfy tax withholding obligations due as a result of settlement of a portion of a restricted stock unit award granted on November 23, 2022. The reporting person has paid to Enanta $13,861.92, representing the full amount of the profit realized in connection with the short-swing transaction."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $5.32 to $5.86, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":846638,"source":{"system":"sec-edgar","filing":"0001062993-25-002225","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299325002225/form4.xml","form_type":"4"}},{"id":1337523,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-12-10T21:55:03.000Z","date":"2024-12-06","kind":"sale","planned":true,"acquired":false,"shares":5142,"price":8.06,"value":41444.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $7.87 to $8.22, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth set forth in this footnote of this Form 4."}],"balance_after":801638,"source":{"system":"sec-edgar","filing":"0001062993-24-020375","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324020375/form4.xml","form_type":"4"}},{"id":1345549,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-12-03T23:28:56.000Z","date":"2024-12-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":3829,"price":8.6,"value":32929.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit awards granted on November 20, 2020 and November 19, 2021."}],"balance_after":806780,"source":{"system":"sec-edgar","filing":"0001062993-24-019974","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324019974/form4.xml","form_type":"4"}},{"id":1349789,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-27T21:59:10.000Z","date":"2024-11-27","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024)."}],"balance_after":250000,"derivative":{"exercise_price":8.83,"expiration_date":"2034-11-27","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001062993-24-019764","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324019764/form4.xml","form_type":"4"}},{"id":1643619,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-02-15T01:00:28.000Z","date":"2024-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":1584,"price":12.41,"value":19657.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU awards."}],"balance_after":810609,"source":{"system":"sec-edgar","filing":"0001062993-24-003223","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324003223/form4.xml","form_type":"4"}},{"id":1643618,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-02-15T01:00:28.000Z","date":"2024-02-12","kind":"grant","planned":false,"acquired":true,"shares":5400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Enanta common stock issued under performance share units (\"PSUs\") that vested as a result of performance against two-year research and development milestones in the calendar 2022-2023 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2024."}],"balance_after":812193,"source":{"system":"sec-edgar","filing":"0001062993-24-003223","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324003223/form4.xml","form_type":"4"}},{"id":1720292,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-12-07T01:17:05.000Z","date":"2023-12-05","kind":"sale","planned":false,"acquired":false,"shares":7230,"price":9.63,"value":69624.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 23, 2022, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $9.49 to $9.63, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth set forth in this footnote of this Form 4."}],"balance_after":806793,"source":{"system":"sec-edgar","filing":"0001062993-23-022045","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299323022045/form4.xml","form_type":"4"}},{"id":1722246,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-12-06T02:08:20.000Z","date":"2023-12-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":5787,"price":9.49,"value":54918.63,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit awards granted on November 20, 2020 and November 19, 2021."}],"balance_after":814023,"source":{"system":"sec-edgar","filing":"0001062993-23-021981","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299323021981/form4.xml","form_type":"4"}},{"id":1731553,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-22T22:10:21.000Z","date":"2023-11-22","kind":"grant","planned":false,"acquired":true,"shares":264000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 22, 2023)."}],"balance_after":264000,"derivative":{"exercise_price":8.99,"expiration_date":"2033-11-22","underlying":"Common Stock","underlying_shares":264000},"source":{"system":"sec-edgar","filing":"0001062993-23-021379","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299323021379/form4.xml","form_type":"4"}},{"id":1954684,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-14T22:26:03.000Z","date":"2023-03-13","kind":"exercise","acquired":false,"shares":27912,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 21, 2013, the reporting person was granted an option to purchase 83,526 shares of common stock, half of which became exercisable upon the achievement of several clinical milestones during the four-year performance period after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":14,"expiration_date":"2023-03-21","underlying":"Common Stock","underlying_shares":27912},"source":{"system":"sec-edgar","filing":"0001062993-23-006867","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299323006867/form4.xml","form_type":"4"}},{"id":1954683,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-03-14T22:26:03.000Z","date":"2023-03-13","kind":"sale","acquired":false,"shares":1566,"price":46.13,"value":72239.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.54, inclusive."}],"balance_after":819810,"source":{"system":"sec-edgar","filing":"0001062993-23-006867","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299323006867/form4.xml","form_type":"4"}},{"id":1954682,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-03-14T22:26:03.000Z","date":"2023-03-13","kind":"sale","acquired":false,"shares":15649,"price":45.31,"value":709056.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive."}],"balance_after":821376,"source":{"system":"sec-edgar","filing":"0001062993-23-006867","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299323006867/form4.xml","form_type":"4"}},{"id":1954681,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-03-14T22:26:03.000Z","date":"2023-03-13","kind":"sale","acquired":false,"shares":10697,"price":44.81,"value":479332.57,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.39 to $44.99, inclusive."}],"balance_after":837025,"source":{"system":"sec-edgar","filing":"0001062993-23-006867","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299323006867/form4.xml","form_type":"4"}},{"id":1954680,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-03-14T22:26:03.000Z","date":"2023-03-13","kind":"exercise","acquired":true,"shares":27912,"price":14,"value":390768.0,"ownership":{"direct":true},"balance_after":847722,"source":{"system":"sec-edgar","filing":"0001062993-23-006867","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299323006867/form4.xml","form_type":"4"}},{"id":2013843,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-16T02:42:25.000Z","date":"2023-02-13","kind":"tax_withholding","acquired":false,"shares":20591,"price":52.77,"value":1086587.07,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards."}],"balance_after":819810,"source":{"system":"sec-edgar","filing":"0001062993-23-003712","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299323003712/form4a.xml","form_type":"4/A","original_submission_date":"2023-02-15"}},{"id":2013842,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-16T02:42:25.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":29146,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4/A is being filed to correct an administrative error in the reported number of securities granted and the amount of securities beneficially owned following the transactions."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of Enanta common stock issued under a relative total stockholder return unit (\"rTSRU\") award granted to the reporting person on December 18, 2020 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 13, 2023."}],"balance_after":840401,"source":{"system":"sec-edgar","filing":"0001062993-23-003712","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299323003712/form4a.xml","form_type":"4/A","original_submission_date":"2023-02-15"}},{"id":2013841,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-16T02:42:25.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":22950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4/A is being filed to correct an administrative error in the reported number of securities granted and the amount of securities beneficially owned following the transactions."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of Enanta common stock issued under a performance share unit (\"PSU\") award granted on December 18, 2020 that vested as a result of the achievement of a research and development milestone in calendar 2022 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 13, 2023."}],"balance_after":811255,"source":{"system":"sec-edgar","filing":"0001062993-23-003712","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299323003712/form4a.xml","form_type":"4/A","original_submission_date":"2023-02-15"}},{"id":2013833,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-16T01:56:50.000Z","date":"2023-02-13","kind":"tax_withholding","acquired":false,"shares":20591,"price":52.77,"value":1086587.07,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards."}],"balance_after":799219,"source":{"system":"sec-edgar","filing":"0001062993-23-003705","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299323003705/form4.xml","form_type":"4"}},{"id":2013832,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-16T01:56:50.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":16220,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of Enanta common stock issued under a relative total stockholder return unit (\"rTSRU\") award granted to the reporting person on December 18, 2020 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 13, 2023."}],"balance_after":819810,"source":{"system":"sec-edgar","filing":"0001062993-23-003705","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299323003705/form4.xml","form_type":"4"}},{"id":2013831,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-16T01:56:50.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":15285,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Enanta common stock issued under a performance share unit (\"PSU\") award granted on December 18, 2020 that vested as a result of the achievement of a research and development milestone in calendar 2022 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 13, 2023."}],"balance_after":803590,"source":{"system":"sec-edgar","filing":"0001062993-23-003705","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299323003705/form4.xml","form_type":"4"}},{"id":2082148,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-20T00:50:58.000Z","date":"2022-12-19","kind":"exercise","acquired":false,"shares":14500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option are fully vested and exercisable."}],"balance_after":55500,"derivative":{"exercise_price":27.58,"expiration_date":"2023-12-05","underlying":"Common Stock","underlying_shares":14500},"source":{"system":"sec-edgar","filing":"0001062993-22-024173","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322024173/form4.xml","form_type":"4"}},{"id":2082147,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-12-20T00:50:58.000Z","date":"2022-12-19","kind":"exercise","acquired":true,"shares":14500,"price":27.58,"value":399910.0,"ownership":{"direct":true},"balance_after":788305,"source":{"system":"sec-edgar","filing":"0001062993-22-024173","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322024173/form4.xml","form_type":"4"}},{"id":2084069,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-17T02:44:28.000Z","date":"2022-12-16","kind":"exercise","acquired":false,"shares":13851,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On March 21, 2013, the reporting person was granted an option to purchase 83,526 shares of common stock, which becomes reportable on Form 4 only if and to the extent that the option becomes exercisable. The option becomes exercisable in up to nine installments, based on Enanta's achievement of certain clinical milestones with respect to three or more programs that progress in clinical development. As of the date of this filing, a total of 50% of the shares subject to the option have become exercisable."}],"balance_after":27912,"derivative":{"exercise_price":14,"expiration_date":"2023-03-21","underlying":"Common Stock","underlying_shares":13851},"source":{"system":"sec-edgar","filing":"0001062993-22-024037","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322024037/form4.xml","form_type":"4"}},{"id":2084068,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-17T02:44:28.000Z","date":"2022-12-16","kind":"exercise","acquired":false,"shares":16149,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"100% of the shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":14.18,"expiration_date":"2022-12-26","underlying":"Common Stock","underlying_shares":16149},"source":{"system":"sec-edgar","filing":"0001062993-22-024037","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322024037/form4.xml","form_type":"4"}},{"id":2084067,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-12-17T02:44:28.000Z","date":"2022-12-16","kind":"sale","acquired":false,"shares":13603,"price":45.49,"value":618800.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.85, inclusive."}],"balance_after":773805,"source":{"system":"sec-edgar","filing":"0001062993-22-024037","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322024037/form4.xml","form_type":"4"}},{"id":2084066,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-12-17T02:44:28.000Z","date":"2022-12-16","kind":"sale","acquired":false,"shares":8597,"price":44.54,"value":382910.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.04 to $44.93, inclusive."}],"balance_after":787408,"source":{"system":"sec-edgar","filing":"0001062993-22-024037","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322024037/form4.xml","form_type":"4"}},{"id":2084065,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-12-17T02:44:28.000Z","date":"2022-12-16","kind":"sale","acquired":false,"shares":7800,"price":43.59,"value":340002.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.29 to $43.99, inclusive."}],"balance_after":796005,"source":{"system":"sec-edgar","filing":"0001062993-22-024037","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322024037/form4.xml","form_type":"4"}},{"id":2084064,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-12-17T02:44:28.000Z","date":"2022-12-16","kind":"exercise","acquired":true,"shares":13851,"price":14,"value":193914.0,"ownership":{"direct":true},"balance_after":803805,"source":{"system":"sec-edgar","filing":"0001062993-22-024037","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322024037/form4.xml","form_type":"4"}},{"id":2084063,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-12-17T02:44:28.000Z","date":"2022-12-16","kind":"exercise","acquired":true,"shares":16149,"price":14.18,"value":228992.82,"ownership":{"direct":true},"balance_after":789954,"source":{"system":"sec-edgar","filing":"0001062993-22-024037","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322024037/form4.xml","form_type":"4"}},{"id":2096567,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-12-06T00:17:13.000Z","date":"2022-12-01","kind":"tax_withholding","acquired":false,"shares":5659,"price":44.33,"value":250863.47,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit awards granted on November 20, 2020 and November 19, 2021."}],"balance_after":773805,"source":{"system":"sec-edgar","filing":"0001062993-22-023359","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322023359/form4.xml","form_type":"4"}},{"id":2103523,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-11-28T23:17:11.000Z","date":"2022-11-23","kind":"grant","acquired":true,"shares":134000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 23, 2022)."}],"balance_after":134000,"derivative":{"exercise_price":45,"expiration_date":"2032-11-23","underlying":"Common Stock","underlying_shares":134000},"source":{"system":"sec-edgar","filing":"0001062993-22-022837","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322022837/form4.xml","form_type":"4"}},{"id":2103522,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-11-28T23:17:11.000Z","date":"2022-11-23","kind":"grant","acquired":true,"shares":63000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Enanta Pharmaceuticals, Inc. (\"Enanta\") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs will vest and settle with respect to 25% of the award on December 4, 2023 and in substantially equal annual installments over the next three anniversaries thereafter."}],"balance_after":779464,"source":{"system":"sec-edgar","filing":"0001062993-22-022837","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322022837/form4.xml","form_type":"4"}},{"id":2394827,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-02-16T02:32:56.000Z","date":"2022-02-14","kind":"tax_withholding","acquired":false,"shares":2355,"price":62.49,"value":147163.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards."}],"balance_after":716464,"source":{"system":"sec-edgar","filing":"0001062993-22-004510","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322004510/form4.xml","form_type":"4"}},{"id":2394826,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-02-16T02:32:56.000Z","date":"2022-02-14","kind":"grant","acquired":true,"shares":6401,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of Enanta common stock issued under a relative total stockholder return unit (\"rTSRU\") award granted to the reporting person on December 20, 2019 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 14, 2022."}],"balance_after":718819,"source":{"system":"sec-edgar","filing":"0001062993-22-004510","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322004510/form4.xml","form_type":"4"}},{"id":2394825,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-02-16T02:32:56.000Z","date":"2022-02-14","kind":"grant","acquired":true,"shares":1627,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Enanta common stock issued under a performance share unit (\"PSU\") award granted on December 20, 2019 that vested as a result of the achievement of a research and development milestone in calendar 2021 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 14, 2022."}],"balance_after":712418,"source":{"system":"sec-edgar","filing":"0001062993-22-004510","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322004510/form4.xml","form_type":"4"}},{"id":2433998,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-18T11:04:23.000Z","date":"2022-01-15","kind":"exercise","acquired":false,"shares":10063,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":11.77,"expiration_date":"2022-06-20","underlying":"Common Stock","underlying_shares":10063},"source":{"system":"sec-edgar","filing":"0001062993-22-001104","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322001104/form4.xml","form_type":"4"}},{"id":2433997,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-01-18T11:04:23.000Z","date":"2022-01-15","kind":"exercise","acquired":true,"shares":10063,"price":11.77,"value":118441.51,"ownership":{"direct":true},"balance_after":710791,"source":{"system":"sec-edgar","filing":"0001062993-22-001104","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299322001104/form4.xml","form_type":"4"}},{"id":2486486,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-12-03T23:33:57.000Z","date":"2021-12-01","kind":"tax_withholding","acquired":false,"shares":1944,"price":87.68,"value":170449.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 20, 2020."}],"balance_after":700728,"source":{"system":"sec-edgar","filing":"0001062993-21-012197","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299321012197/form4.xml","form_type":"4"}},{"id":2499116,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-11-24T00:23:19.000Z","date":"2021-11-19","kind":"grant","acquired":true,"shares":107800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 19, 2021)."}],"balance_after":107800,"derivative":{"exercise_price":75.33,"expiration_date":"2031-11-19","underlying":"Common Stock","underlying_shares":107800},"source":{"system":"sec-edgar","filing":"0001062993-21-011498","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299321011498/form4.xml","form_type":"4"}},{"id":2499115,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-11-24T00:23:19.000Z","date":"2021-11-19","kind":"grant","acquired":true,"shares":25700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Enanta Pharmaceuticals, Inc. (\"Enanta\") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs vest in equal annual installments over four years from the date of grant (November 19, 2021). The restricted stock unit shares that vest will be issued on the first December 1 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements."}],"balance_after":702672,"source":{"system":"sec-edgar","filing":"0001062993-21-011498","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299321011498/form4.xml","form_type":"4"}},{"id":2566337,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-09-17T21:17:30.000Z","date":"2021-09-15","kind":"sale","acquired":false,"shares":4516,"price":59.0562,"value":266697.7992,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $59.00 to $59.23, inclusive."}],"balance_after":676972,"source":{"system":"sec-edgar","filing":"0001177648-21-000025","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764821000025/edgar.xml","form_type":"4"}},{"id":2942903,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2020-12-16T23:20:06.000Z","date":"2020-12-15","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Restricted stock units convert into ENTA common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On November 18, 2016, the reporting person was granted 15,000 restricted stock units. 7,500 restricted stock units have previously vested and the remainder vested on November 18, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On November 18, 2016, the reporting person was granted 15,000 restricted stock units. 7,500 restricted stock units have previously vested and the remainder vested on November 18, 2020."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001177648-20-000051","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764820000051/edgar.xml","form_type":"4"}},{"id":2942902,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-12-16T23:20:06.000Z","date":"2020-12-15","kind":"tax_withholding","acquired":false,"shares":2201,"price":42.52,"value":93586.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of the restricted stock unit award."}],"balance_after":681488,"source":{"system":"sec-edgar","filing":"0001177648-20-000051","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764820000051/edgar.xml","form_type":"4"}},{"id":2942901,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-12-16T23:20:06.000Z","date":"2020-12-15","kind":"exercise","acquired":true,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of ENTA common stock subject to a restricted stock unit award granted on November 18, 2016 that vested on November 18, 2020.  The settlement and issuance of the shares was subject to continued employment and occurred on December 15, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Restricted stock units convert into ENTA common stock on a one-for-one basis."}],"balance_after":683689,"source":{"system":"sec-edgar","filing":"0001177648-20-000051","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764820000051/edgar.xml","form_type":"4"}},{"id":2971512,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-11-21T01:21:39.000Z","date":"2020-11-20","kind":"grant","acquired":true,"shares":107800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 20, 2020)."}],"balance_after":107800,"derivative":{"exercise_price":43.57,"expiration_date":"2030-11-20","underlying":"Common Stock","underlying_shares":107800},"source":{"system":"sec-edgar","filing":"0001177648-20-000035","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764820000035/edgar.xml","form_type":"4"}},{"id":2971511,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-11-21T01:21:39.000Z","date":"2020-11-20","kind":"grant","acquired":true,"shares":26500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Enanta Pharmaceuticals, Inc. (\"Enanta\") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs vest in equal annual installments over four years from the date of grant (November 20, 2020). The restricted stock unit shares that vest will be issued on the first December 1 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements."}],"balance_after":676189,"source":{"system":"sec-edgar","filing":"0001177648-20-000035","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764820000035/edgar.xml","form_type":"4"}},{"id":3267122,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-02-18T11:03:50.000Z","date":"2020-02-12","kind":"tax_withholding","acquired":false,"shares":3122,"price":52.76,"value":164716.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards."}],"balance_after":649689,"source":{"system":"sec-edgar","filing":"0001177648-20-000006","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764820000006/edgar.xml","form_type":"4"}},{"id":3267121,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-02-18T11:03:50.000Z","date":"2020-02-12","kind":"grant","acquired":true,"shares":8910,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of Enanta common stock issued under a relative total stockholder return unit (\"rTSRU\") award granted to the reporting person on March 1, 2018 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2020."}],"balance_after":652811,"source":{"system":"sec-edgar","filing":"0001177648-20-000006","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764820000006/edgar.xml","form_type":"4"}},{"id":3267120,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-02-18T11:03:50.000Z","date":"2020-02-12","kind":"grant","acquired":true,"shares":1485,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Enanta common stock issued under a performance share unit (\"PSU\") award granted on March 1, 2018 that vested as a result of the achievement of a research and development milestone in calendar 2019 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2020."}],"balance_after":643901,"source":{"system":"sec-edgar","filing":"0001177648-20-000006","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764820000006/edgar.xml","form_type":"4"}},{"id":3318768,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2020-01-06T23:18:44.000Z","date":"2019-12-16","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Restricted stock units convert into ENTA common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On November 18, 2016, the reporting person was granted 15,000 restricted stock units. 7,500 restricted stock units vested on November 18, 2019 and the remainder will vest on November 18, 2020, subject to the reporting person's continued employment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents shares of ENTA common stock subject to a restricted stock unit award granted on November 18, 2016 that vested on November 18, 2019.  The settlement and issuance of the shares was subject to continued employment and occurred on December 16, 2019."}],"balance_after":7500,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001177648-20-000002","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764820000002/edgar.xml","form_type":"4"}},{"id":3318767,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-01-06T23:18:44.000Z","date":"2019-12-16","kind":"tax_withholding","acquired":false,"shares":3330,"price":63.88,"value":212720.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of the restricted stock unit award."}],"balance_after":642416,"source":{"system":"sec-edgar","filing":"0001177648-20-000002","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764820000002/edgar.xml","form_type":"4"}},{"id":3318766,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-01-06T23:18:44.000Z","date":"2019-12-16","kind":"exercise","acquired":true,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of ENTA common stock subject to a restricted stock unit award granted on November 18, 2016 that vested on November 18, 2019.  The settlement and issuance of the shares was subject to continued employment and occurred on December 16, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Restricted stock units convert into ENTA common stock on a one-for-one basis."}],"balance_after":645746,"source":{"system":"sec-edgar","filing":"0001177648-20-000002","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764820000002/edgar.xml","form_type":"4"}},{"id":3368625,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2019-11-18T23:45:31.000Z","date":"2019-11-18","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 18, 2019)."}],"balance_after":110000,"derivative":{"exercise_price":63.35,"expiration_date":"2029-11-18","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001177648-19-000038","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764819000038/edgar.xml","form_type":"4"}},{"id":3395439,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2019-10-09T21:17:58.000Z","date":"2019-10-08","kind":"exercise","acquired":false,"shares":7052,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option are fully vested and exercisable."}],"balance_after":16149,"derivative":{"exercise_price":14.18,"expiration_date":"2022-12-26","underlying":"Common Stock","underlying_shares":7052},"source":{"system":"sec-edgar","filing":"0001177648-19-000035","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764819000035/edgar.xml","form_type":"4"}},{"id":3395438,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-10-09T21:17:58.000Z","date":"2019-10-08","kind":"exercise","acquired":true,"shares":7052,"price":14.18,"value":99997.36,"ownership":{"direct":true},"balance_after":638246,"source":{"system":"sec-edgar","filing":"0001177648-19-000035","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764819000035/edgar.xml","form_type":"4"}},{"id":3660699,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-02-14T02:16:27.000Z","date":"2019-02-12","kind":"tax_withholding","acquired":false,"shares":20730,"price":88.88,"value":1842482.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards."}],"balance_after":631194,"source":{"system":"sec-edgar","filing":"0001177648-19-000009","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764819000009/edgar.xml","form_type":"4"}},{"id":3660698,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-02-14T02:16:27.000Z","date":"2019-02-12","kind":"grant","acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of Enanta common stock issued under a relative total stockholder return unit (\"rTSRU\") award granted to the reporting person on January 4, 2017 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2019."}],"balance_after":651924,"source":{"system":"sec-edgar","filing":"0001177648-19-000009","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764819000009/edgar.xml","form_type":"4"}},{"id":3660697,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-02-14T02:16:27.000Z","date":"2019-02-12","kind":"grant","acquired":true,"shares":14400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Enanta common stock issued under a performance share unit (\"PSU\") award granted on January 4, 2017 that vested as a result of the achievement of a clinical development milestone in calendar 2018 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2019."}],"balance_after":615924,"source":{"system":"sec-edgar","filing":"0001177648-19-000009","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764819000009/edgar.xml","form_type":"4"}},{"id":3756822,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2018-11-21T00:45:52.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":68000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 16, 2018)."}],"balance_after":68000,"derivative":{"exercise_price":81.2,"expiration_date":"2028-11-16","underlying":"Common Stock","underlying_shares":68000},"source":{"system":"sec-edgar","filing":"0001177648-18-000040","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000040/edgar.xml","form_type":"4"}},{"id":3859153,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2018-07-30T20:57:01.000Z","date":"2018-07-27","kind":"exercise","acquired":false,"shares":8498,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":11.7663,"expiration_date":"2022-06-20","underlying":"Common Stock","underlying_shares":8498},"source":{"system":"sec-edgar","filing":"0001177648-18-000032","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000032/edgar.xml","form_type":"4"}},{"id":3859152,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-07-30T20:57:01.000Z","date":"2018-07-27","kind":"exercise","acquired":true,"shares":8498,"price":11.7663,"value":99990.0174,"ownership":{"direct":true},"balance_after":601524,"source":{"system":"sec-edgar","filing":"0001177648-18-000032","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000032/edgar.xml","form_type":"4"}},{"id":3871229,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-07-09T20:56:17.000Z","date":"2018-07-06","kind":"sale","acquired":false,"shares":4125,"price":127.1222,"value":524379.075,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $126.80 to $127.52, inclusive."}],"balance_after":593026,"source":{"system":"sec-edgar","filing":"0001177648-18-000030","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000030/edgar.xml","form_type":"4"}},{"id":3871228,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-07-09T20:56:17.000Z","date":"2018-07-06","kind":"sale","acquired":false,"shares":7738,"price":126.3618,"value":977787.6084,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $125.80 to $126.79, inclusive."}],"balance_after":597151,"source":{"system":"sec-edgar","filing":"0001177648-18-000030","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000030/edgar.xml","form_type":"4"}},{"id":3871227,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-07-09T20:56:17.000Z","date":"2018-07-06","kind":"sale","acquired":false,"shares":7538,"price":125.2673,"value":944264.9074,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $124.80 to $125.79, inclusive."}],"balance_after":604889,"source":{"system":"sec-edgar","filing":"0001177648-18-000030","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000030/edgar.xml","form_type":"4"}},{"id":3871226,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-07-09T20:56:17.000Z","date":"2018-07-06","kind":"sale","acquired":false,"shares":12622,"price":124.264,"value":1568460.208,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $123.75 to $124.74, inclusive."}],"balance_after":612427,"source":{"system":"sec-edgar","filing":"0001177648-18-000030","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000030/edgar.xml","form_type":"4"}},{"id":3871225,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-07-09T20:56:17.000Z","date":"2018-07-05","kind":"sale","acquired":false,"shares":2977,"price":123.8051,"value":368567.7827,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $123.75 to $124.02, inclusive."}],"balance_after":625049,"source":{"system":"sec-edgar","filing":"0001177648-18-000030","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000030/edgar.xml","form_type":"4"}},{"id":3925997,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-05-18T22:02:39.000Z","date":"2018-05-17","kind":"sale","acquired":false,"shares":10968,"price":105.8299,"value":1160742.3432,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $105.75 to $106.35, inclusive."}],"balance_after":628026,"source":{"system":"sec-edgar","filing":"0001177648-18-000026","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000026/edgar.xml","form_type":"4"}},{"id":3925996,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-05-18T22:02:39.000Z","date":"2018-05-16","kind":"sale","acquired":false,"shares":14032,"price":105.8233,"value":1484912.5456,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $105.75 to $106.00, inclusive."}],"balance_after":638994,"source":{"system":"sec-edgar","filing":"0001177648-18-000026","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000026/edgar.xml","form_type":"4"}},{"id":4063086,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-02-13T23:27:38.000Z","date":"2018-02-12","kind":"tax_withholding","acquired":false,"shares":11132,"price":76.845,"value":855438.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards."}],"balance_after":653026,"source":{"system":"sec-edgar","filing":"0001177648-18-000005","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000005/edgar.xml","form_type":"4"}},{"id":4063085,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-02-13T23:27:38.000Z","date":"2018-02-12","kind":"grant","acquired":true,"shares":20737,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of Enanta common stock issued under a relative total stockholder return unit (\"rTSRU\") award granted to the reporting person on December 21, 2015 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2018."}],"balance_after":664158,"source":{"system":"sec-edgar","filing":"0001177648-18-000005","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000005/edgar.xml","form_type":"4"}},{"id":4063084,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-02-13T23:27:38.000Z","date":"2018-02-12","kind":"grant","acquired":true,"shares":8600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Enanta common stock issued under a performance share unit (\"PSU\") award granted on December 21, 2015 that vested as a result of the achievement of a clinical development milestone in calendar 2018 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2018."}],"balance_after":643421,"source":{"system":"sec-edgar","filing":"0001177648-18-000005","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764818000005/edgar.xml","form_type":"4"}},{"id":4154518,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2017-11-22T00:56:04.000Z","date":"2017-11-17","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 17, 2017)."}],"balance_after":100000,"derivative":{"exercise_price":48.52,"expiration_date":"2027-11-17","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001177648-17-000037","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764817000037/edgar.xml","form_type":"4"}},{"id":4352052,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2017-04-14T20:13:10.000Z","date":"2017-04-12","kind":"grant","acquired":true,"shares":13925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On March 20, 2013, the reporting person was granted an option to purchase 83,526 shares of common stock, which becomes reportable on Form 4 only if and to the extent that the option becomes exercisable.  The option becomes exercisable in up to nine installments, based on Enanta's achievement of certain clinical milestones with respect to three or more programs that progress in clinical development. This report reflects the additional shares that became exercisable upon achievement of two of the milestones. As of the date of this filing, a total of 50% of the shares subject to the option have become exercisable."}],"balance_after":13925,"derivative":{"exercise_price":14,"exercise_date":"2017-04-12","expiration_date":"2023-03-20","underlying":"Common Stock","underlying_shares":13925},"source":{"system":"sec-edgar","filing":"0001177648-17-000024","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764817000024/edgar.xml","form_type":"4"}},{"id":4445930,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-02-15T22:43:03.000Z","date":"2017-02-13","kind":"tax_withholding","acquired":false,"shares":2278,"price":29.815,"value":67918.57,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares of common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU award."}],"balance_after":634821,"source":{"system":"sec-edgar","filing":"0001177648-17-000006","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764817000006/edgar.xml","form_type":"4"}},{"id":4445929,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-02-15T22:43:03.000Z","date":"2017-02-13","kind":"grant","acquired":true,"shares":6800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock issued upon vesting of a performance share unit (\"PSU\") award granted on February 20, 2015 as a result of the achievement of a clinical development milestone in 2016 and the settlement and issuance of those shares of common stock on Febuary 13, 2017."}],"balance_after":637099,"source":{"system":"sec-edgar","filing":"0001177648-17-000006","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764817000006/edgar.xml","form_type":"4"}},{"id":4545265,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2016-11-22T22:53:37.000Z","date":"2016-11-18","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Restricted stock units convert into shares of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Such restricted stock units will vest as to one half the shares on the third anniversary of the date of award (November 18, 2019) and the remainder on the fourth anniversary of the date of award (November 18, 2020). The restricted stock unit shares that vest will be issued on the first December 15 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Such restricted stock units will vest as to one half the shares on the third anniversary of the date of award (November 18, 2019) and the remainder on the fourth anniversary of the date of award (November 18, 2020). The restricted stock unit shares that vest will be issued on the first December 15 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001177648-16-000008","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764816000008/edgar.xml","form_type":"4"}},{"id":4545264,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2016-11-22T22:53:37.000Z","date":"2016-11-18","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 18, 2016)."}],"balance_after":120000,"derivative":{"exercise_price":30,"expiration_date":"2026-11-18","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001177648-16-000008","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000117764816000008/edgar.xml","form_type":"4"}},{"id":4592639,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66533,"kind":"person","name":"Luly Jay R.","position":1,"cik":"0001571211","reported_name":"Luly Jay R.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2016-09-29T21:24:55.000Z","date":"2016-09-28","kind":"grant","acquired":true,"shares":6957,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On March 20, 2013, the reporting person was granted an option to purchase 83,526 shares of common stock, which becomes reportable on Form 4 only if and to the extent that the option becomes exercisable.  The option becomes exercisable in up to nine installments, based on Enanta's achievement of certain clinical milestones with respect to three or more programs that progress in clinical development. This report reflects the additional shares that became exercisable upon achievement of one of the milestones. As of the date of this filing, a total of 33.33% of the shares subject to the option have become exercisable."}],"balance_after":6957,"derivative":{"exercise_price":14,"exercise_date":"2016-09-28","expiration_date":"2023-03-20","underlying":"Common Stock","underlying_shares":6957},"source":{"system":"sec-edgar","filing":"0001571211-16-000004","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000157121116000004/edgar.xml","form_type":"4"}}]}